CA1318462C - Synthetic resin - Google Patents

Synthetic resin

Info

Publication number
CA1318462C
CA1318462C CA000562701A CA562701A CA1318462C CA 1318462 C CA1318462 C CA 1318462C CA 000562701 A CA000562701 A CA 000562701A CA 562701 A CA562701 A CA 562701A CA 1318462 C CA1318462 C CA 1318462C
Authority
CA
Canada
Prior art keywords
group
formula
resin
synthetic resin
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA000562701A
Other languages
French (fr)
Inventor
Hans Rink
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Priority to CA000616052A priority Critical patent/CA1322008C/en
Application granted granted Critical
Publication of CA1318462C publication Critical patent/CA1318462C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08FMACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00Chemical modification by after-treatment
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/042General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers characterised by the nature of the carrier
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08FMACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00Chemical modification by after-treatment
    • C08F8/30Introducing nitrogen atoms or nitrogen-containing groups
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08FMACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00Chemical modification by after-treatment
    • C08F8/50Partial depolymerisation

Abstract

4-16403/+
Synthetic resin Abstract A synthetic resin based on a polystyrene that cna be used as a support for soild phase peptide synthesis and that has been cross-linked with from 0 to 5 mol% of divinyl benzene, characterised in that it has been substituted at benzene rings of its skeletal structure by groups of the formula (I) in which X represents -O- or -NH- and R represents C1-C4-alkyl, as a support renders possible the solid phase synthesis of peptides and peptide amides that are, if desired, protected at the N-terminal and/or at other functional groups. The resin is manufactured by reaction of a customary chloromethylated polystyrene resin with an alkali metal salt of the corresponding 4-hydroxybenzophenone and subsequent reduction of the carbonyl group and, optionally, amination.
.

Description

~ 3 ~

4-16~iO3 Synthetic resin The inventlon relates to a novel synthetic resin for ~lse as a support for the synthesis of peptides and peptide amldes in solid phase in accordance with the known general principle of the Merrifield synthesis. The syn-thetic resin according to the invention consists of the skeletal struc-ture of a polystyrene that can be used for such a Merrifield synthesis and that has optionally been cross-linked by copolymerisation with from O
to 5 mol%, preferably from 1 to 2 mol%, of divinyl ben~ane and is characterised in that it has been substituted at benzene rings of its skeletal structure by groups of the formula RO
-CH2-O-~ H~ OR (I~

in which X represents -O- or -NH- and R represents C1-C4-alkyl. X in a resin according to the invention is preferably -O-, and the symbol R is preierably a linear C1-C4-alkyl, especially ~ethyl.

The invention also relates to a process for the manufacture o~ the above-characterised resin and to its use for the manuacture of peptides and peptide amides, especially those that are protected at the N-terminal amino group and/or at the remaining ~unctional groups. The invention relates also to corresponding resins in which the radical -XH~ when it represents -NH2, is ln protected form, and to resins with attached, optionally protected, amino acid, peptide and peptide amide residues, and also to the free peptides and peptide amides manufactured by the above-mentioned process, especially those described in the Examples.

The principle of the Merrifield synkhesis of peptidic compounds, pub-lished in 1962, i0 generally known. In this process, an amino acid protected at one terminal (usually the ~-terminal) is bonded (attached~

t ~ 1 ~

to a suitab~y functionalised base polymer (in the most common form to a chloromethylated polystyrene). The bond should on the one hancl be sufficiently strong to remain intact under the various reaction con-ditions of the synthetic construction of the peptide (especially the removal of the N-terminal amino-protecting group), but on the other hand should allow the Elnished peptide to be detached from the polymer support under cond:Ltions that do not impair the product. The actual synthesis is then carried out at the amino acid that is attached to the support; in this process usually the N-terminal protecting group is removed, the freed amino group is acylated by a suitable amino acid derivative pro-tected at the N-terminal (that is to say a new peptidic bond is formed), and the removal of the terminal protecting group and acylation with a further amino acid residue is repeated until an amino acid sequence of the desired length is obtained. This sequence is then detached (removed) from the support as -the finished peptide by means of a suitable reagent. This ideal reaction course suffers from a number of disadvantages and sources of errors when carried out in practice, and over the last 25 years peptide literature has been actively concerned with these problems. One of the most difficult problems is that the synthesised sequence on the support cannot be freed of secondary products, and a defective structure tha~t has already been formed (for example a secondary product with a shortened sequence) co-reacts in every further stage of the synthesis and is carried over into subsequent stages so that, at the end, the desired product is often obtained only in a small quantity together with a predominant mass of secondary products of similar structure from which it has to be separated in a complicated manner. This situation is especially di~ficult if the amino acids used contain other side chain functional groups that must virtually always be protected (owing to the relatively energetic conditions in the acylation operation). Thesa protecting groups, in turn, must be sufficiently resistant to remain intact when the N-terminal amino group is freed. Yet another problem is posed by peptide amides since their bond to the support (in contrast to the ester bond of conventional peptides~, is also a peptidic bond like the bond between amino acids of the complete amino acid sequence. The difficulty therefore arises of selectively detaching a peptide amide from the suppor~ whilst retaining the other peptidic bonds.

_ 3 _ ~3~

For these (and also other) reasons, solid p~ase synthesis (Merrifield synthesis) is currently regarded as a method having certain advAntages only when synthesislng peptides having a maximum of 30 amino acids.

In order to broaclen its field of application, it has been proposed, see, for example, E. Atherton et al., Proceedings of the 7th American Peptide Symposium, pages 163-195, Pierce Chemical Company, RockEord, IL, U.S.A.
(1981)~ that entire amino acid partial sequences having protected functional groups (including the N-terminal amino group) be attached in the form o~ building blocks to a support and linked with other protected peptide fragments in the form of building blocks. It should, then, be possible also to produce these necessary building blocks ~peptide fragments) by solid phase synthesis on a support. This, however, presents an entirely new problem. For this, a resin is required that permits the synthesised peptide fragment, which consists of several protected amino acid residues, to be released from attachment to the resin under such mild and/or selective conditions that neither the ~-terminal protecting group nor the protecting groups cf other functional groups (which of necessity must be different from the former) are affected. A detailed discussion of various proposals and partial solutions can be found in the above-mentioned publication of Atherton et al.; these authors have themselves proposed as their own best solution the use of a polyamide base resin that is bonded by way of norvaline to 2- or 3-methoxy-4 hydroxymethylphenoxyacetic acid. The C-terminal of the first ~protected~
amino acid is then attached to the hydroxymethyl group by an ester bond;
the cleaving o~ this bond (detachment from the resin) at the end of the synthesis is effected using 1 % trifluoroaceti acid in methylene chloride. But even this method, which can probably be considered as one of the best in the State of the Art, is not universally applicable since, as stated by the authors themselves, under the removal conditions at the end of the synthesis at least two very important protecting groups of the side chains, that is the tert.-butoxycarbonyl protecting group of the s-amino group of lysine and the tert.-butyl group protecting the hydroxy group of tyrosine, are so easily removed that the use of these protecting groups becomes questionable. Moreover, the resin is not suitable for a _ 4 _ ~ 3.~ ~3 l~

direct solid phase synthesis of peptide amides. All of thls probably explains why this me-thod has not been more wiclely used so far in spite oE
its clear advantages.

Surprisin~ly, it has now been found that the synthetic resin according to the inventlon is free from the known disadvantages of the earlier proposals and thus permits a w:ide application of the solid phase synthesis of protected and unprotected peptides and peptide amides.
Preferably, the most used support polymer, that is polystyrene, is used as the polymer skeleton for the synthesis of the synthetic resin.

Practically any synthetic resin that contains phenyl groups in its ske-leton can be used as the base polymer. Polymers of styrene, which have been in general use for 20 years as supports for the solid phase synthe-sls of peptides and which are available in the form of various commercial preparations for that purpose, are preferred. In order to increase the stability and insolubility in organic solvents, polystyrene resins that have been cross-linked by copolymerisation with at most 5 mol%, and pre-ferably approximately from 1 to 2 mol%, divinyl benzene, are preferred.
Such base polymers are substituted at their phenyl groups (benzene rings) by chloromethylation or bromomethylation and then the actual anchor groups are introduced at the methylene group by exchanging chlorine or bromine, respectively. Also, halomethylated, especially chloromethylated, polystyrene resins are common commercial products which, under the name "Merrifield resin", are widely used in the solid phase synthesis of pep-tides.

The process according to the invention for the manufacture of the above-defined novel synthetic resins comprises reacting a suitable polystyrene, for example an above-described polystyrene cross-linked with from 0 to 5 mol% divinyl benzene and chloromethylated or bromomethylated at benzene rings of the skeletal structure, in succession, a) with a compound of formula RO\
M-O~ CO~ OR ~II), ~ 3 ~ 8 ~ ~ ~d in which M is an alkali metal and R has ~he meaning given above, b) with a reducing agent and, if X represents -Nfl-, c) with a reagent that introduces the amino grolJp.

The reaction according to process step a) is carried out in the presence of a highly polar solvent that preferably has a good dissolving capacity for salts, for example a dipolar aprotic solvent, such as dimethyl sulphoxide, acetonitrile, hexamethylphosphorus triamide, N,N'-propylene urea or an alipha~ic amide, such as, especially, dimethylformamide, or also mixtures of the mentioned solvents and, preferably, with the strict exclusion of moisture. Preferably a solution of the alkali metal salt of formula II is used; a caesium salt (M is caesium) is especially suitable for that purpose. The reaction can be carried out at temperatures of from 0 to 50C, preferably in the region of room temperature, the reaction times accordingly extending to several, for example from 8 to 72, hours.
During that time, the reaction mixture i8 preferably stirred or shaken mechanically~ The 2,4-dialkoxy-4'-hydroxyben20phenones used as starting material can be obtained in a manner known per se, for example by C-acylation of a corresponding resorcinol diether with p-hydroxybenzoyl chloride catalysed by aluminium chloride, or by a modification of this acylation; the desired salt is obtained therefrom by conventional reaction with the corresponding alkali metal hydroxide, such as caesium hydroxide.

Process step b) is carried out in a manner lcnown per se by reaction with a reducing agent, for example one that is customary for reducing oxo groups to hydroxy groups. Suitable reducing agents are, for example, diborane or complex hydrides, such as, especlally, alkali metal boro-hydrides (for example sodium borohydride, lithium borohydride or po-tassium borohydride~ as well as, also, alkali metal aluminium hydrides (for example sodium aluminium hydride or lithium aluminium hydride~, which are used in expedient non-reactive organic solvents, especially open-chained or cyclic ethers (for example diisopropyl ether or 1,2-di-methoxy- or -diethoxy-ethane, or dioxan or tetrahydrofuran, respectively) at temperatures of from 0 to approximately 100C, depending on the re-agent. The reaction times depend on the reagents and reaction conditions employed and as a rule range from 1 to 48 hours; shaking or stirring - 6 - ~ 3 ~

facilitate~ contact between the solid and :Liquid components. If neces-sary, the reductio~ process can be repeated with a fresh amount of re-ducing agent; excess reagent is advantageo-Jsly destroyed at the end of the reaction, for example by a ketone, such as acetone.

The optional process step c), which is used to convert the "hydroxy resin" obtained in accordance with b) into the "amino resin", is carried out, for example, with ammonia. For this purpose, for example ammonia gas is introduced into a stirred s~spension of the "hydroxy resin" in a polar solvent, for example one of the solvents mentioned in process step a) or b), at temperatures of from 0C to room temperature; this process can especially also be carried out under elevated pressure at temperatures of up to 50C with sha~ing.

Carbamates from which the alcohol moiety can be removed by treatment with a base but which are stable under acidic reaction conditions are espec-ially suitable as the reagents for introducing the amino group used in process s~ep c). Examples of such carbamates are substituted ethyl-carbamates that carry activating, especially electron-attracting, sub-stituents in the ~-position. The following are suitable: ~-(lower alkane-or arenesulphonyl)-ethylcarbamates, for example ~-(methanesulphonyl)-ethylcarbamate or ~-(benzenesulphonyl)-ethylcarbamate, ~-(nitro-, cyano-or halo-phenyl)-ethylcarbamates, for example ~ -nitrophenyl)-ethyl-carbamate, ~-di-(~-nitrophenyl)-ethylcarbamate or ~-(pentafluorophenyl)-ethylcarbamate, or especially 9-fluorenylmethylcarbamate. In the reaction wlth the abo~e-mentioned carbamates a suspension of the "hydroxy resin"
in an inert organic solvent, ~or example a halohydrocarbon, such as methylene chlorlde, chloro~orm or 1,2-dichloroethane, or an ether, such as diisopropyl ether, dlisobutyl ether, dimethoxyethane, dlethoxyethane, tetrahydrofuran or dioxan, is stirred at temperatures of from 20 to gOC, preferably of approximately 50C, with the carbamate and a strong acid, for example an organic sulphonic acid, preferably a lower alkane-sulphonic or arenesulphonic acid, for example methanesulphonic acid, benzenesulphonic acid or p-toluenesulphonic acid, for a few hours, for sxample from 2 to 48 hours. In this manner a synthetic resin of the above-defined structure is obtained that carries instead of the -X-H
group a -N~-W group in which W represents an amino-protecting group that ~ 3 ~ o 2l489-7~04 can be removed by treatment with A basr?, especially a substltlJted ethoxy-c~rbonyl group. I`o E~eo the "nmlno le!lil~" Lhc protecl::lng grol~p ln tlla lemoved with a base, ~or examplc wit:ll n ;o1ution of a terl::Lary or, prererab1y, secondary, open-chained ol cyclic amine, Eor example tr:l-etl~ylamine, tributylam:ine, die~:llylamille, ~)iperldloe~ pyrrolicline or morpholine, in an inert organic solvell~ refernbly in one of the ~I~OVO
mentioned ethers or ln a di-lower alkylamide, for exnmple dimethyl-formamide or dim~thylacetamide, at temperatures oE Erom 0 to 50C, prefernbly at approx:lmately ~oom tempera~uro, with renction time~ of frotn a few minutes, for example 1 minute, to a few hours, for example 6 hours.
It is also possible to use an alkali metal hydroxide, for example sodium hydroxlde, or an ammonium hydroxide, fol cxample hen%yltrimcthylnmmonl~
llydroxide, instead of an amlne, ln whicll case, even ~t loweL temperA-ture~, the cleaving is already concludcd aftcr shorter reactlon tlme~, for example after less than 1 minute.

As already mentloned hereinbefore, the invention also relateD to the use of the synthetlc resln according to the inventlon as a support for the sol1d phase syhthesis of peptid~s and peptide amides, especially those that are protected at the N-terminal amino group and/or at functlonal ~roups of the side chains.

In accordance with the invention, the peptid;ic compounds are manufactured using the above-defined synthetic resin as follows:
a) the synthetic re~in is reacted with a compound of formula W1-A~I1'-Y-H
in which Y represents -0- or -NH-, Wl represents a~ N-terminal amino-protecting group and AM1 repreDent6 the acyl rad:lcal of an amlno acid sequence consisting of fro~ 1 to 25 amino acid resldue~ which i8, if desired, protected at functlonal groups, or wlth a reactlve'functional derlvative thereof, for the purpose of attachlng the residue W1-AM'- to an -X- group of the resin, wherein X represents -O- or -NH-, b) the N-terminal protecting group W1 is removed, c) the Eread N-termlnal amino group is acylated by reaction wlth an acid of formula W~-AM2-OH ln which w2 and AM2 have meanings analogous to those of the above-deflned radical3 Wl and AMI, or wlth a reactive functional derivat~ve thereof, :~ 3 ~

d) the operation of alternate removal according to b) and acylation according to c) i5 repeated as required until the dssirecl amino acid sequence i5 obtained and e) the resulting peptide or peptide amide, if desired after the remova~
or simultaneously with the removal of protecting groups, i5 removed Erom the resin by acidolysis.

When attaching the C-termina] protected amino acid or arnino acid sequence to the resin of the invention, the conditions are always chosen taking into account the reacting functional groups concerned. The support resin preferably used is the "hydroxy resin" of formula I in which X represents -0-; if the end product is desired in the amide form, that resin can be reacted with a protected amino acid amide or with a protected amino acid sequence that is in the form of an aMide, for example with a compound of formula Wl-AMI-NH2 in which Wl and A~l are as defined above, in which reaction the hydroxy groups -X~ of the resin are exchanged for the amidic C-terminal amino group. The attachment reaction is usùally acid-catalysed, for example by means of an organic sulphonic acid, preferably a lower alkanesulphonic or an arenesu]phonic acid, for example methane-sulphonic acid, benzenesulphonic acid or ~-toluenesulphonlc acid, and carried out in the presence of inert organic solvents, such as chlorinated alkanes ~for example methylene chloride, chloroform or 1,2-dichloroethane) and/or open-chained or cyclic ethers ~for example di-ethyl, diisopropyl or dibutyl ether, or l,2-dimethoxy- or 1,2-diethoxy-ethane, or dioxan or tetrahydrofuran, respectively? for several, for example from 2 to 48, hours at temperatures of from 20 to 80C, prefer-ably at approximately 50C. If necessary the attachment operation can be repeated. The resin with attached C-terminal amide, that is to say one in which the benzene rings have been substituted by radicals of the formula RO\
-CH2-O~ ~OR (III) H-AMI -Wl in which R, Wl and AM~ have the meanings given above, is then subjected to the synthesis of the desired amlno acid sequsnce in accordance with process steps b) to d). The detachment of the finished peptide amide (process step e) can be carried out with hydrogen fluoride, but is _ 9 _ ~ 3 ~ 2 preferably carried out with milder acidic agents, sucll as triEluoroacetic acid, preferably in an inert organic cliluent, suh as a haloalkane, or in water. For example, the detachment is carried out using a mlxture o~
triEluoroacetic acid and methylene chloride or 1,2-dichloroethane, for example ln a ratio by volume of 1:1. Ilowever, not all o~ the acido-lytically removable protecting groups customarily used are resistant under these conditions. Dependin~ on the reactLon procedure, therefore, at the same time as the detachment from the resin the corr0sponding protecting groups are also removed, resulting in a peptide amide having free functional groups.

If the peptide at the end of the synthesis is desired in the form of a free acid ~if desired with an N-terminal protecting group and/~r other protecting groups), then the support resin used is again the "llydroxy resin" of formula I in which X represents -O-. This is reacted with a protected amino acid or with a protected amino acid sequence in the form of the free acid or in the form of a reactive functional derivative of the acid, for example with a compound of formula Wl-AMI-OH in which Wl and AMI are as defined hereinbefore, in which reaction the hydroxyl group of the resin is esterified. The attachment reaction is carried out under acylation conditions customary in peptide synthesis. The reactive functional derivative used is, or example, an anhydride of the acid to be attached, especially a symmetrical anhydride, preferably in the presence of organic tertiary bases, such as those mentioned hereinafter.
Another suitable functional derivative is an active ester of the acid to be attached, which is also reacted in the presence of the organic tertiary bases mentioned hereinafter. Suitable active esters ar~ espec-ially esters of phenols that carry electron attracting substituents, and esters of N-hydroxyimides. Preferably, however, the compound to be attached is used in the form of the free acid and is acylated with the aid of carbodiimides9 for example diisopropylcarbodiimide or especially dicyclohexylcarbodiimide, as condensation agent. The reaction is carried out in the presence of organic bases, especially tertiary bases (such as pyridine, quinoline, 4-dimethylaminopyridine, N-methylpiperidine, N-methylmorpholine, N,N'-dimethylpiperazine, or triethylamine or diiso-propylethylamine) and in inert organic solvents, such as chlorinated alkanes (for example methylene chloride or chloroform) andlor open--10- ~3~ 2 chained or cyclic e-thers (for example diethyl, di:isopropyl or dibutyl ether, or 1,2-dimethoxy- or 1,2-diethoxy-ethane, or dioxan or tetra-hydrofurcln, respectively~. AT1 activated N-hydroxy compouncl, for example l-hydroxybenzotria~ole, is preferably added. The reaction time is as a rule several, such as from 2 to 48, hours at temperatures of from 0 to 40C; if desired the acylation process can be repeated. AS a means of avoiding undesired secondary products it is advantageous to treat the resulting resin with benzoyl chloride (or a similar simple acid derivative) in the presence of a base, such as one of those mentioned hereinbefore, and thus block the hydroxy groups of the resin which may still ba free. The resin with attached C-terminal ester, that is to say one in which the benzene rings have been substituted by radicals oE
formula RO\
-Cl12-O-~ -OR (IV), I--wl in which R, Wl and AM1 have the meanings given hereinbefore, is then subjected to the synthesis of the desired amino acid sequence in accordance with process steps b) to d). If an end product without protecting groups, especially without acid-labile protecting groups, is desired, the detachment of the finished peptide acid (process step e) can be carried out with hydrogen fluoride, but is preferably carried out with milder acidic agents, such as trifluoroacetic acid, which is preferably diluted with an inert organic solvent, such as a haloalkane. If a pep-tide (amino acid sequence) is desired in which the N-terminal amino group and/or the other functional groups are retained in protected fo~m, as is usually desirable in the case of peptide fragments that are to be used for further synthesis, the detachment of the end product from the resin is carried out under especially mild acidolytic conditions, for example with an organic acid, especially a lower alkanecarboxylic acid, prefer-ably formic or propionic acid or, more especially, acetic acid, which may be diluted with neutral organic solvents9 for example chlorinated alkanes or aliphatic or cyclic ethers; there may be mentioned as being especially advantageous, for example, a mixture oE acetic acid and methylene chloride or chloroform in a ratio by volume of from approximately 1:1 to approximately 1:19, especially of 1:9. Also suitable are highly diluted trifluoroacetic acid, for example in the form of a 0.1 to 2 % solu~ion in methylene chloride or chloroform, or a pyridinium salt, for example pyridinium hydrochloride, in a polar, salt- ancl peptide-dissolving solvent, for example in dimethylacetamide or dimethylformamide. The detachment is usually carried out in a temperature range of from 0 to 50~C, preferably in the region of room temperature, the reaction time extending from a few minutes to several (for example Erom 2 to 8) hours.

It is also possible to obtain peptide amides using as the support resin the "amino resin" of formula I in ~hich X represents -NH- and reacting it with a protected amino acid or protected amino acid sequence in the form of the free acid or in the form of a reactive functional derivative of the acid, for example ~itll a compound of formula Wl-A~l-OH in which W
and AMI are as defined hereinbefore. This results in a resin with an attached C-terminal amide, that is to say a resin in ~hich the benzene rings have been substituted by radicals of formula III. The reAction is preferably carried out under the reaction conditions mentioned above for the esterification of the "hydroxy resin" with free acid or a reactive functional derivative thereof. Tbe synthesis of the desired amino acid sequence according to process steps b) to d) and the detachment of the finished peptide amide according to process step e) are then carried out exactly as described hereinbefore.

The relative ease with which the amino acid sequence can be detached from the resin is determlned by the special choice of the N-terminal amino-protecting groups, the removal of which must be strictly selective, with the sequence remalning a-ttach~d to the resin (and also with the retention of other protecting groups) 7 but nevertheless quantitative. Thls N-terminal amino-protectlng group Wl or w2 is preferably a group that can be removed under basic conditions, especially a group of the oxycarbonyl type. Preferred N-terminal amino-protecting groups Wl and w2 are sub-stituted ethoxycarbonyl groups that carry in the R-position activating, especially electron-attracting, substituents, such as those mentioned hereinbefore in the case of the corresponding carbamates. Especially suitable are the ~-(methanesulphonyl)-ethoxycarbonyl group, the ~ nitrophenyl)-ethoxycarbonyl group and the ~-di-(~-nitrophenyl)-ethoxycarbonyl group, and more especially the 9-fluorenylmethoxycarbonyl - 12 - ~3 ~ 2 group (Fmoc). These protecting grol~ps can be removed with inorganic or organic bases, especially with tertiary or secondary amlnes, such as those mentioned hereinbeFore for the manufacture oE the ~amino resin".
The condltions for the removal of the N-terminal amino-protecting ~roup in accordance with process step b), especially of the ~moc group, are described hereinbefore in connection with the manufacture of the "amino resin" and are generally known.

The acylation of the freed N-terminal amino group in accordance with process step c) is carried out under generally customary conditions that are common Eor solid phase synthesis, especially on a Merrifield support.
Of the numerous known variants, attention is drawn in particular to that in which the acylation is carried out with an amino acid (or amino acid sequence) protected at the N-terminal by Fmoc or by an equivalent base-labile protecting group, in which all the functional groups of the side chain are in protected form7 or with a reactive functional derivative of that acid, for example the symmetrical anhydride or an active ester. If the ~ree acid is used, then the condensation agent employed is dicyclo-hexylcarbodiimide (or an analogous reagent), preferably in combination with 1-hydroxybenzotriazole, and in the presence of tertiary organic bases, for example tertiary aliphatic or cyclic amines or heteroaromatic bases, such as triethylamine, diisopropylethylamine, ~,N-dimethylaniline, N-methylpiperidine, N-ethylpiperidine, N-methylmorpholine, N,N~-dimethyl-piperazine, or pyridine and homologues thereof, quinoline or 4-dimethyl-aminopyridine. The acylation with the symmetrical anhydride or the active ester is also carried out in the presence of the mentioned tertiary bases and preferably also in the presence of 1-hydroxybenzotriazole. Suitable active esters are esters with phenols that carry electron-attracting substituents 9 for example p-nitrophenol, pentafluorophenol or 2,4,5-trichlorophenol, or with N-hydroxyimides, for example with N-hydroxy-succinimide or N-hydroxy-norbornane- or 5-norbornene-2,3-dicarboxylic acid imide. The acylstion conditions of the mentioned variants are generally known; if desired, the acylation process can be repeated and/or, in order to prevent the formation of incorrect sequences, the residual non-acylated starting material can be acylated in a conventional ~ 3 ~
manner with a simple carboxylic acid derivative, such as acetic anhydride or acetyl chloride, and thus blocked from Eurther undesired acylations by amino acid residues in later stages of the synthesis.

Suitable amino acid residues for the synthesis according to the invention are those derived from naturally occurring ~-amino acids of the L-series especially in the form of peptide 'building blocks, and closely related analogues thereoE, such as, especially, the enantiomers of the "unnatural" D-series. Preferred ~-amino acids are, for example, glycine, alanine, valine, leucine, isoleucine, phenylalanine, aspartic acid, glutamic acid7 arginine, histidine and lysine, and also ~-amlnobutyric acid, norvaline, isovaline, norleucine, ornithine and citrulline, as well as asparagine, glutamine, tyrosine, tryptophan, methionine, threonine, serine, but also proline and hydroxyproline (in which the ~-amino group is combined with the alkyl radical to form a ring), and also cysteine and cystine (the latter occurring as a pair of 2 cysteine residues bonded together, which may also be located at positions of the sequence separ-ated from one another). ~lso suitable are residues of other amino acids that are derived from C1-C7-alkanecarboxylic acids, especially linear ones, and that carry the amino group in any position of the chain, for example at the terminal C-atom (such as in ~-alanine, ~-aminobutyric acid or ~-aminovaleric acid); in addition they may also carry ot'her primary amino groups (as in ~, r-diaminobutyric acid~ or be substituted by other functional groups, such as hydroxy, mercapto, disulphido, guanidino, carboxy or carboxamide groups, or by cyclic hydrocarbyl or heterocyclyl radicals, such as phenyl, ~-hydroxyphenyl, indolyl or imidazolyl. I~ they contain asymmetric C-atoms these amino acids may be used in racemic form or, preferably, in optically active form.

The specific charactsr of the solid phase synthesis demands that func-tional groups in the amino acid residues used that do not participate in the reaction (and also those that can remain free in liquid phase syntheses) are as a rule in protected form.

The choice of protecting groups depends on the conditions of the synthesis and on the use of the end product to be produced. If several functional groups are to be protected then advantageous combinations must - 14 - ~ 3 ~ ~ ~t~ ~

be selected. In particular, care should be taken tha~ protectlng groups of functional groups of the amino aci~ side chains are resistant durirlg the removal of the N-terminal protecting group, such as the Fmoc group, and, i~ a protected peptide building block for a Eurther synthesis is desired as end produc-t, that they are stable under the mild aeidic conditions employed for the detachment from the resin at the end of the synthesis .

To protect other amino groups present, such as ~he s-amillo group in the lysine residue, it is possible to use any amino-protecting group custom-ary in peptide chemistry that is stable under weakly basic conditions.
Suitable groups are described collectively in known reference works, for example in Houben-Weyl; Methoden der organischen Chemie, 4th edition, vol 15/I, ~. Wunsch (editor), Synthese von Peptiden (Georg Thieme Verlag, Stuttgart, 1974).

It is thus possible to use, for example, amino-protecting groups that can be removed by reduction or under energetic basic conditions, for example especially the benzyloxycarbonyl group and benzyloxycarbonyl groups that have been substituted in the aromatic moiety by halogen atoms, nitro groups, lower alkoxy groups and/or lower alkyl radicals, such as the ~-chloro- or ~-bromo-benzyloxycarbonyl, ~-nitrobenzyloxycarbonyl, p-me-thoxybenzyloxycarbonyl or ~-tolylmethoxycarbonyl group, and also the isonicotinyloxycarbonyl group, as w011 as also sulphonyl groups such as ~-toluenesulphonyl, benzenesulphonyl, o-nitroben2enesulphonyl and other suhstituted benzenesulphonyl groups or also acyl groups, such as ~ormyl, trifluoroacetyl or phthaloyl. An advantageous amino-p}otecting group is an ethoxycarbonyl group that carries in the ~-positlon a silyl group substituted by three hydrocarbon radicals, such as triphenylsilyl, di-methyl-tert.-butyl-silyl or, especially, trimethylsilyl. Such a ~-(tri~
hydrocarbylsilyl)~ethoxycarbonyl groupg such as a ~-(tri-lower alkyl-silyl)~ethoxycarbonyl group, for example especially the ~~(trimethyl~
silyl)-ethoxycarbonyl group, is resistant under the conditions of acidic hydrolysis and of hydrogenolysis, but can be removed under quite spe-cific, very mild conditions by the action of fluoride ions. In this re-spect it behaves analogously to the ~-silylethyl ester group described hereina~ter as a carboxy-protecting group.

3~

More especially preferred are groups that can be removed by acidolysis,such as, especially, tert.-butoxycarbony~ and analogous groups, for example the tert.-amylox~ycarbonyl, isopropoxycarbonyl, di:Lsopropyl-methoxycarbonyl, allyloxycarbonyl, cyclopentyloxycarbonyl, cyclohexyl-oxycarbonyl, d-isobornyloxycarbonyl and adamantyloxycarbonyl groups, and also groups oE the aralkyl type, such as benzhydryl and ~riphenylmethyl (trityl), and also aralkoxycarbonyl groups of the 2-aryl-~-propoxycar bonyl type, for example the 2-phenyl- or 2-~-biphenylyl-2-propoxycarbonyl groups.

It is possible for one of the above-mentioned amino-protecting groups to be used as a protecting group of the guanidino function, as occurs, Eor example, in the natural amino acid arginine. Especially suitable are sulphonyl groups, especially lower alkanesulphonyl~ for example methane-, ethane- or isopropane-sulphonyl groups, or arenesulphonyl, for example substituted benzenesulphonyl, groups, suitable substituents being lower al~yl, for example methyl, lower alkoxy, for example methoxy, fused lower alkoxy, for example 1-oxa-1,4-butylene, nitro or halogen, for example chlorine or bromine. The 2,3,5-trimethyl-4-methoxybenzenesulphonyl group and the 2,2,5,7,8-pentamethyl-chroman-6-sulphonyl group are especially preferred.

It is possible to use as a hydroxy-protecting group any group customaryin peptide chemistry for that purpose, cf. the above-cited review in ~ouben-Weyl. Groups that can be removed by acidolysis, such as 2-tetra-hydropyranyl and more especially tert.-butyl, as well as, also, tert.-butoxycarbonyl, are preferred. It is also possible, however, to use hydroxy-protecting groups that can be removed by reduction or under basic conditions, for example benzyl ox benzyloxycarbonyl groups which may be substituted in the aromatic moiety by halogen, nitro and/or by lower alkoxy, lower alkanoyl radicals, such as acetyl, or aroyl radicals, such as benzoyl.

It is possible to use as a carboxy-protecting group any group customaryfor that purpose, cf. the above-cited review in Houben-Weyl. Thus, carboxy groups are protected, for example, by hydrazide formation or by - 16 - ~ 3 .~

esterification~ The ~ollowing, for example, are suitable ~or the esteri-fication: lower, optionally substituted alkanols, such as methanol, ethanol, cyanomethyl alcohol, 2,2,2-trichloroethanol, ben~oylmethyl alcohol or, especially, tert.-butyl alcohol, but also an optionally sub-stituted benzyl alcohol. An especially advantageous category of sub-stituted alkanols are ethanols carrying a trisubstituted silyl group, such as triphenylsilyl, dimethyl-tert.-butyl-6ilyl or, especially, tri-methylsilyl, in the ~-position. These alcohols are especially su:Ltable for the protection of carboxy groups because the corresponding ~-silyl-et:hyl esters, for example ~-(trlmethylsilyl)ethyl ester, do indeed have the stability of customary alkyl es-tars, but can be removed selectively with fluoride ions whilst all other protecting groups are retained.

There may be used as a mercapto protecting group any group customary inpeptide chemistry for that purpose. The mercapto groups are protected especially by suitable acylation or alkylation. The following, for example, are suitable for the acylation: the acetyl or benzoyl radical, a lower al~yl- (for example ethyl-) carbamoyl group, or a benzyloxycarbonyl group optionally substituted as indicated hereinbefore. The following, for example, are suitable for the alkylation: the tert.-butyl, isobutoxy-methyl, benzylthiomethyl or tetrahydropyranyl radical, or arylmethyl radicals optionally substituted by halogen, lower alkoxy or by nitro, such as benæyl, ~-methoxybenzyl, diphenylmethyl, dimethoxybenzhydryl or, more especially, trityl, as well as, also, phenylcyclohexyl, p-methoxy-phenylcyclohexyl, or 2-thienylcyclohexyl. An acylaminomethyl radical in which acyl is, for example, acetyl or alternatively benzoyl, is also very advantageous. The acetylaminomethyl group is especially preferred.

Preferably, the protecting groups of the side chains are so selected that they can all be remoYed under similar conditions; especially preferred are the groups to which attention has already been drawn that can be removed by acidolysis, especially those derived from tert.-butyl. The removal of all of these protecting groups is then advantageously carried out in a single operation.

- 17 - ~3~ 2 The protecting groups are removed in generally known manner. The acido-lysis or acidic hydrolysis is carried out, for exampLe, hy means of trL-fluoroacetic acid, hydrochloric acid or hydrogen fluoricle, anfl in the case of readily removable protecting groups a:lso by means of a lower aliphatic carboxylic. acid, such as formic acid and/or acetic acid, in the presence of a halo~enated hydrocarbon, for example methylene chloride, or of water and optionally a polyhalogenated lower alkanol or lower alkanone, such as 1,1,1,3,3,3-hexafluoropropan-2-ol or hexafluoroacetone.
The groups that can be removed by reduction, especially those that contain benzyl radicals, are removed preferably by hydrogenolysis, for example by hydrogenation catalysed by palladium. The isonicotinyloxy-carbonyl group is preferably removed by zinc reduction. The ~-silyl-ethoxycarbonyl group is cleaved by fluoride ions.

The invention relates also to the intermediates and end products of thesyn~hesis process using the resin according to the invention. The in-vention relates especially to a synthetic resin of the structure defined at the beginning that instead of the -X-H group carries an -NH-W, -X-AM-W
or -X-AM-H group in which -X- represents -0- or -NH-, W represents an N-terminal amino-protecting group and AM represents the acyl radical of an amino acid sequence consisting of from 1 to 18~ amino acid residues which, if desired, is protected at functional groups, especially one of the compounds described in the following Examples. The invention relates also to peptides and peptide amides of formula W-AM-XH in which -X-represents -O- or -NH-, W represents a terminal amino protecting group and AM represents the acyl radical of an amino acid sequenc~ consisting of from 2 to 180 amino acid residues which, if desired, is protected at functional groups, and to analogous compounds having a free N-terminal amino group of formula H-AM -XH, insofar as they can be obtained by the synthesis process according to the invention, especially to th0 peptides and peptide amides described in the following Examples.

The abbreviations used, for example for the designation of amino acids,peptides and protecting groups etc., are customary abbreviations, for example the abbreviations compiled in the above-cited review in Houben-Weyl. Unless stated otherwise, the names and abbreviations of amino acid residues refer to residues of ~-amino acids of the naturally occurring L-series. Unless indicated to the contrary, the term "lower" when used in connection with an organic radical or compound indLcates such a radicaL
or compound having a maxLmum oE 7, but preferably a max:Lmum of 4, carbon atoms.

In the following Examples the invention i5 illustrated further without the scope thereof be:Lng limited in any way. The abbreviations used have the ~ollowing meanings:

Boc - tert.-butoxycarbonyl But - tert.-butyl (in ether) TLC - thin layer chromatography DCCI - dicyclohexylcarbodiimide DMA - dimethylacetamide DMF - dimethylformamide DMSO - dimethyl sulphoxide EDC - 1,2-ethane dichloride FAB-MS - Past Atom Bombardment Mass Spectrum Fmoc - 9-fluorenylmethoxycarbonyl HOBt - 1-hydroxybenzotriazole HPLC - high pressurs liquid chromatography IGF-2 - Insulin-like Growth Factor-2 MIF - Macrophage migration Inhibition Fackor Mtr - 2 ? 3,5-trimethyl-4-methoxybenzenesulphonyl OBut - tert.-butyl (in ester) TFA - trifluoroacetic acid THF - tetrahydrofuran Trt - trityl Example 1: 2,4-dimethoxy-4'-hydroxy-benzophenone (1) The title compound is synthesised analogously to the preparation of 2,4'-dihydroxy-4-methoxy-bsnzophenone, see Ray, S., Grover, P.K. and Anand Nitya: Indian Journal of Chemistry 9, 619-623 (1971), from resorcinol dimethyl ether and 4-hydroxybenzoic acid. Elemental analysis, IH-NMR spsctrum and IR spectrum confirm the structure of ~1).

- 19 - ~3~ 2 Ex~mele 2: Caesium salt of 2,4-dlme~hoxy-4'-hyclroxyben~o,ohenone (lA) 5.00 g of (1) (19.3 mmol) are suspended in 40 ml of ethanol and 16 ml oE
water and a solution of 3.25 g (l9 mmol) o~ caesium hyclroxide monohydrate in 4.5 ml of water is added. The solution is concentrated in vacuo, taken up in 40 ml of water/tert.-butyl alcohol (1:1) and lyophilised. The slightly yellowish lyophilisate, when crystallised Erom 20 ml of tert.-butyl alcohol, yields the salt (lA) in the form of a white powder.
xample 3: 4-(2,4-dimethoxyben~oyl)-phenoxymethyl-polystyrene (1 ~0 DV~
cross-linked) (2) 20.0 g of chloromethyl-polystyrene-l % divinylbenæene (DVB) (= Merrifield polymer Fluka, Switzerland; O.fi7 mmol Cl/g) (13.4 mmol) are dried under a high vacuum for 1 hour at 50C. 26.1 g of (lA) (67 mmol) are suspended three times, with approximately 500 ml of pyridine each time, followed by concentration by evaporation under a high vacuum, and the resldue is dissolved in approximately 700 ml of dry DM~ and concentrated to approxi-mately 400 ml under a high vacuum. The resin is added and the reaction mixture is shaken at room temperature for 20 hours with the exclusion of moisture. The resin is filtered and washed w:ith 100 ml portions of the following solvents: 3 x isopropyl alcohol, 3 x DMF, 3 x water, 3 x DMF, 5 x water, 4 x isopropyl alcohol. The resin :is dried under a high vacuum at from 40 to 45C until constant mass is reached. The IR spectrum exhibits the expected C=O band.
xample 4: 4-(?,4-dim _h xyphenyl-hydroxy-methyl)-phenoxymethyl-poly-styrene ~dimethoxybenæhydryloxymethyl-polystyrene, "hydroxy resin"] (3) 14.5 ml of lM lithium borohydride in THF ars added to a suspension of 7.07 g of (~) ~approximately 4.8 mmol ketone function) in 50 ml of dry tetrahydrofuran (THF) and the reaction mixture is refluxed for 1 hour with the exclusion of moisture. After the mixture has been cooled to approximately from 0 to 5C, 24 ml oE methanol and, dropwise while stirring well, approximately 6 ml of acetone, are added. The filtered resin is washed as follows using 30 ml portions of solvont: 3 x methanol, 1 x water, 1 x aqueous hydrochloric acid of p~ approximately 3.0, 2 x - 20 - ~3~ 2 water, 4 x me~hanol. The resin is dried under a high vacuum at Erom 40 to 45C until constant mass is reached ~lemental analysis: 3.67 Y~ O =
2.31 mmol O/g, IR spectrum: no C=O band.

Example 5: N-[Fmoc-Pro~-4-(2~4-dimethoxyphenyl-amino-methyl)-phen .. .. . . _ _ methylpolystyrene [Fmoc-Pro-amino resin] (4) A mixture of 0.46 g of (3) (approximately 0.26 mmol)~ 0.31 g of Fmoc-Pro-N~12 (0.92 mmol), 76.5 ~1 of lM benzenesulphonic acid solution in di-chloromethane (76.5 llmol) and 10 ml of dioxan is stirred for 3 hours and, after the addition of a further 76.5 ~1 of lM benzenesulphonic acid solution, is stirred for a further 20 hours at 50C. The resin is filtered and washed as follows, using 5 ml portions of solvent: 5 x methanol, 12 x dichloromethane, 3 x methanol, 3 x dichloromethane. The resin is dried under a high vacuum at from 40 to 45C until constant mass is reached.
Using a sample weighing approximately 20 mg, the Fmoc group is removed by 4 x 2 minute trea-tments with 300 ~1 of 20 % piperidine each time and washing six times with dimethylacetamide (DMA). The spectrophotometric determination (300 nm) gives a specific loading of 0.23 mmol of Fmoc/g of resin.

Example 6: N-[Boc-Pro-Glu~OBut)-Ile-Pro]-amino resin (5) 0.42 g of (4) (97 ~mol) is reacted to form (5) in an automatic peptide synthesiser by means of the following process by successive alternate removal of the Fmoc group and condensing (coupling) with Fmoc-Ile, Fmoc-Glu(OBut) and Boc-Pro, in each case with unreacted amino groups being blocked by acetylation.

Individual operations:
Washing and removal ~deblocking) of Fmoc at room temperature with in each case approximately 10 ml: 1 x isopropyl alcohol (1 min.), 4 x DMA
degassed (0.5 min.), 1 x isopropyl alcohol (l min.), 3 x D~ degassed (0.5 min.), 4 x 20 % piperidine in DMA (2 mins.), 2 x waterldioxan (1:1) (1 min.), 5 x DMA degassed (0.5 min.), 3 x DMA dist. (0.5 min.).
3~3~

Couplin~ 0.39 mmol of N-protected amino acid, 0.68 ml oE 0.57M
1-hydroxybenzotriazole (~IO~t) in DMA ~0.39 mmol) and 0.l8 ml of 2.4M
dicyclohexylcarbodiimide (DCCI) in DMA with the addition of 0.20 m:L oE
DMA (20 mins. at room temperature, 2 hours at 40).
Was~ and _etylation oE the remaining free amino groups with: 1 x acetic anhydride/pyrid:lnet~ (1:1:8 vol.) (5 mins.), 3 x DMA degassed, 1 x isopropyl alcohol (I min.), 3 x DMA degassed (0.5 min.). The resin is washed with isopropyl alcohol (3 x 5 ml) and dried at room temperature under a high vacuum.

Example 7: H-Pro-Gl~-Ile-Pro-NH2 0.46 g of (5) (approximately 90 ~mol) are stirred at room temperature Eor 15 minutes in trifluoroacetic acid/dichloromethane (1:1 vol.) and the resin is filtered off and washed 3 times with approximately lO ml of dichloromethane each time. The filtrate is concentrated in vacuo to approximately 2 ml and, while stirring, is introduced dropwise into 10 ml of ether. The precipitate is filtered off and dried in vacuo. According to thin layer chromatography and HPLC the resulting colourless powder is identical to authentic tetrapeptide amide produced in solution.

Example 8: O-[Fmoc-Glyl-hydroxy resin (6) 2.0 g of (3) (app}oximately 1 mmol), 1.19 g of Fmoc-Gly-OH (4 mmol) and 0.87 g of DCCI (4.2 mmol) are stirred for 5 minutes at from O to 5C in 20 ml of 1,2-ethane dichloride (EDC), 24 mg of 4-dimethylaminopyridine (D~P) (0.2 mmol~ are added and, after a further 20 minutes at approxi-mately 5C, 110 ~l of N methylmorpholine (1 mmol) are added. The mixture is stirred at room temperature for 4 hours. The filtered resin is washed in a peptide synthesiser with 20 ml each time of the following solvents:
3 x methanol, 3 x EDC~ 3 x DMA, in each case for 0.5 minutes. To block hydroxy groups still present in ths resin, the latter is stirred at room temperature for 2 hours with 1.23 g of benzoic acid anhydride (5.4 mmol) in 1.2 ml of pyridine and 6 ml of DMA and then washed as follows, each time with 20 ml: 2 x isopropyl alcohol, 3 x DMA degassed, 2 x isopropyl alcohol, 6 x EDC, 2 x isopropyl alcohol, 3 x DMA degassed, 3 x isopropyl alcohol, in each case for 0.5 minutes. The title compound (6), dried at 45C under a high vacuum, has a Fmoc content of 0.26 mmollg.

- 22 - ~ 3~ 2 Example 9_ O-[Fmoc-R-Ala]-hydr_xy resin (7) The title cnmpound (7) is manufactured analogously to (6) ancl has an ~moc content of 0.33 mmol/g.

Example 10: O-[Fmoc-Le-l-Pro-Glu(O~u~)-Gly-Ser(But)-Pro-Val-Thr(But)-~ ------ ~-- -- -- -- -- -- -- -- -- -- ------ -- -- ---- _ _ _ .. ... _ _ _ _ _ Leu-Asp(OBut?-Leu-Arg(Mtr)-Tyr(But)-Asn-Arg(Mtr? Val-Arg(Mtr)-Val-~-Ala]-hydroxy resin _side chain-protected eglin fragment-~-Ala5sl-eglin C(37-55)-nonadecapeptide bonded to hydroxy res:in), (8) l.lO g of ~7) (0.36 mmol) from Example 9 are reacted in a peptide synthesiser with washing processes and Pmoc removal processes analogously to Example 6. Amino acids 10 to 18 (that is 46 to 54 of eglin C) are coupled in the form of 2,4,5-trichlorophenyl ester (1.08 mmol) in 1.8 ml of DMA, with the addition of 1.89 ml of 0.57M HOBt (1.08 mmol) and 0.285M
diisopropylethylamine (0.54 mmol) in DMA, for two hours at room tempera-ture. This process is repeated for amino acids 11, 12, 16 and 18 (that is 47, 48, 52 and 54 of eglin C). Amino acids 1 to 9 (that is 37 to 45 of eglin C) are used for the coupling in the form oE symmetrical anhydrides (1.08 mmol): 2.16 mmol of Fmoc-amino acid are dissolved in 1~ ml of di-chloromethane (in the case of Fmoc-Gly-OH with the addition of 1 ml of DMA), 245 mg of DCCI (1.12 mmol) are added at room temperature while stirring, the whole is maintained at room temperature for 15 minutes, the precipitated dicyclohexylurea is filtered off, 2.5 ml of DMA (distilled) are added to the filtrate and the dichloromethane is removed in vacuo.
This mixture is added in each case to the synthetic resin and, after the addition of 58 ~l of diisopropylethylamine (0.36 mmol~, maintained at room temperature for 1 hour. Whén the synthesis is complete and the termlnal Fmoc group has been removed in the manner described in Ex-ample 5s the resin is washed 3 times with 5 ml of isopropyl alcohol each time and dried at room temperature under a high vacuum.

Example 11_ Side chain~protected ~-Alas5]-e~ 37-55?-nonapeptide 1.55 g of (8) (approximately 33 ~mol) from Example 10 are s-tirred for 1.5 hours at room temperature with 20 ml of dichloromethane/acetic acld (9:1 vol.), the resin is filtered off and washed as follows with 10 ml of solvent each t-lme: 3 x dichloromethane, 4 x methanol, 4 x dichloro-methane. The original filtrate is combined with the washing solutions and - 23 - ~ 3~ 2 concentrated in vacuo, approximately 5 ml of acetic acid are aclded and the whole i9 lyophilised to dryness yielding the title compound in the form of a colourless powder. IIPLC on Nucleosil 5C1a, 25 x 4.6 mm, gradient: 100 % A/0 ~ B ~ 0 % A/100 % B for 60 minutes, A = water 0.1 %
TFA, B = acetoni~rile 0.1 % TFA, retention time 52 mins. Preparative HPLC: 10 mg are dissolved in 500 ~1 of trifluoroethanol/acetonitrile (1:1), separation is carried out with the above gradient and column and the main ~raction is collected and concentrated by evaporation. In this manner 6.8 mg of a product are obtained which, accordiDg to HPLC, contains more than 90 % of the title compound.

Example 12: 0-[Fmoc-Asp(OBut)-Ar~(M-tr?-Gly-Phe-Tyr(But)-Phe-Ser(But)-Arg(Mtr)-Pro-Ala-Ser(But)-Arg(Mtr)-Val-Ser(But)-Arg(Mtr)-Ar~(Mtr)-Ser(But)-Arg(Mtr)-Gly]-hydroxy resin (side chain-protected IGY-2 (23~41)-nonadecapeptide bonded to hydroxy resin), (9) 1.20 g of (6) (0.31 mmol) from Example 8 are reacted in a peptide synthesiser with washing processes and Fmoc removal processes analogously to Example 6. All the amino acids are used for the coupling (1 hour) in the form of symmetrical anhydrides (3 equivalents, manufacture as in Example 10). With the amino acids 14, 17 and 18 (that is 36, 3~ and 40 of IGF-2) the coupling process is repeated (1 hour). When the synthesis is complete, the resin is washed 3 times with 5 ml of isopropyl alcohol each time and dried under a high vacuum.

Example 13: Fmoc-As ~ ut)-Arg(Mtr)-Gly-Phe-Tyr(But)-Phe=Ser(~ut)-Arg(Mtr)-Pro-Ala-Ser(But?-Arg(M-tr)-Val-Sar(But)-Ar~(Mtr)-rg(Mtr)-Ser(But)-Ar~(Mtr)-Gly-OH [Fmoc-protected IGF-2(23-4I)-nonadecapeptide]
1.65 g of (9) (approximately 154 ~Imol) from Example 12 are cleaved with 33 ml of dichloromethane/acetic acid (9:1 vol.) and washed, analogously to Example 11. Lyophilisation yields a colourless powder. For purifi-cation, this product is partitioned in an automatic countercurrent pa~titioDing apparatus (5 ml/phase~ with a methanol/water/chloroform/
carbon tetrachloride mixture (2700:675:900:1575) over 1050 stages.
Fractions 46-75 contain the pure title compound (TLC, HPLC) and are together concentrated by evaporation, and the residue is triturated with ~ m~

- 24 - ~3 ~

ether and filtered. According to TLC (4 systems on silica gel) and HPI,C
~system as in Example 11; retention time 57 mins.) the resulting colour-less powder is homogeneous.
~AB-MS (fAst atom bombarclment mass spectrum): correct mass p~a~ (2480).
xample 14: Fmoc-amino resin (10) and amino re.sin [4-(2,4-dimethoxy-phenyl-am -methyl)-phenoxymethylpolystyrene]
4.1 g of hydroxy resin (3) (approximately 1.89 mmol) are suspended in 80 ml of dioxan. 1.35 g of 9-fluorenylmethylcarbamate (5.65 mmol) (manu-factured in accordance with Carpino, L.A. et al., J. Org. Chem. 48, 661 (1983)) and 0.47 ml of lM benzenesulphonic acid in 1,2-ethane dichloride (EDC) (0.47 mmol) are added and the mixture is maintained at 50C for 3 hours. After the addition of a further 0.47 ml of lM benzenesulphonic acid, the whole i9 reacted for a further 17 hours at 50C. The resin is filtered and washed with 30 ml portions of the following solvents: 3 x isopropyl alcohol, 3 x EDC, 1 x dimethylacetamide (DMA), 6 x isopropyl alcohol, 3 x DMA. The resin is then maintained at room temperature for 2 hours with 5.0 g of benzoic acid anhydride in 25 ml of DMA and 5 ml of pyridine in order to block unreacted hydroxy groups, and washed as described above. The last wash is carried out with 6 x isopropyl alcohol.
The resulting Fmoc-amino resin (10) is then dried under a high vacuum until a constant mass is reached. After clea~ing a sample in accordance with Example 5, the spectrophotometric determination of FMOC gives a specific loading of approximately 0.35 mmol of Fmoc/g of resin.

In order to produce the free amino resin, 2.0 g of Fmoc-amlno resin (10) in 30 ml o~ 20 % piperldine in dimethylacetamide (DMA) are stirred at room temperature for 1 hour, filtered, treated again with a further 30 ml of 20 % piperidine in DMA for 1 hour, and washed as follows with 30 ml portions: 3 x DMA, 3 x isopropyl alcohol, 3 x D~, 6 x isopropyl alcohol.
The resin is dried under a high vacuum until a constant mass is reached.
xample 15: N-[Met-Hls(Trt)-Glu(OBut)-Gly-Asp(oBut)-Glu(oBut)-Gly-pr Gly]-amino resin (11?
0.50 g of Fmoc-amino resin (10) (approximately 175 ~mol) from Example 14 are reacted in an automatic peptide synthesiser by means of the following proress by successive alternate removal of the Fmoc group and condensing - 25 - ~ 3~ 2 on of Fmoc-Gly, Fmoc-Pro, Fmoc-Gly, Fmoc-Glu(O~Ilt), Fmoc-Asp(O~ut), Fmoc-Gly, Fmoc-Glu(OBut), Fmoc-His(Trt) and Fmoc-~let, unreacted amino groups in each instance being blocked by ace~ylation:
Washing and removal (deblocking) of Fmoc at room temperature with approximately 10 ml each time: 1 x isopropyl alcohol (1 min.) 7 4 x DMA
degassed (0.5 min.), 6 ~ 20 % piperidlne in DMA (2 mins.), 2 x DMA
degassed (0.5 min.), 1 x isopropyl alcohol (1 min.), 4 x DMA de~assed (0.5 min.), 3 x DMA dist. (0.5 min.).
Couplin~: 0.52 mmol of protected amino acid 2,4,5-trichlorophenyl ester and 0.92 ml of 0.57M l-hydroxybenzotriazole (HOBt)/0.57M diisopropyl-ethylamine in DMA (0.52 mmol) with the addition of 0.88 ml of DMA
(30 mins. at room temperature).
Washin~ and _cetylatlon of the remaining free amino groups with: 1 x acetic anhydride/pyridine/DMA (1:1:8 vol.) (5 mins.), 3 x D~ degassed (0.5 min.), 1 x isopropyl alcohol (1 min.), 3 x DMA degassed (0.5 min.).
The terminal Fmoc group is removed in the manner described above. The resin is washed with isopropyl alcohol and dried under a high vacuum a-t room temperature.
xample 16: Met-His-Glu-Gly-Asp-Glu-Gly-Pro-Gly-NH2 (MIF-related protein 14 (94-102)-amide) 0.65 g of (11) (approximately 150 mmol) from Example 15 are washed in a column for 60 mins. with approximately 30 ml of 2 % trifluoroacetic acid ~TFA) in dichloromethane, the eluate is concentrated in vacuo to approxi-mately 0.3 ml, 1 ml of TFA/water (95:5 vol.) is added and the whole is left at room temperature for 15 mins. for complete removal of the pro-terting groups. The peptide amide is precipitated by the addition of 5 ml of diisopropyl ether. The precipitate iB filtered off and dried in vacuo.
The product is dissolved in 5 ~1 of water, the turbid portion is centri fuged off and the supernatant is lyophilised. A colourless powder is obtained which, according to HPLC, is more than 90 % title compound.
HPLC: retention time 6.8 mins., Nucleosil column 7Clg, 120 x 4.6 mm, - 26 - ~ 2 gradient: 100 % A/O % B ~ 10 % A/90 % B in 30 mins., A = 0.l % TFA/water, B = 0.1 ~O TFA/acetanitrile, 1.5 ml/min., detection at 215 nm. FAB-MS:
mass peak 927 (M~

Example 17: 0~[Fmoc-Ala-Tyr(BIlt)-Arg(Mtr)-Pro-Ser(But?-Glu(OBut)-Thr(But?-Leu-Cys(Trt)-Gly-Gly Glu(OBut)-Leu-Val-Asp(O-But)-Thr(But)-Leu-Gln-Phe-Val-Cys(SBut)-Gly]-hydroxy resin (side chain protected_IGF-? (1-22)-docosapeptide bonded to hydr xy resin), (12) 1.00 g of 0-[Fmoc-Gly]-hydroxy resin (6) (approximately 0.36 mmol) are reacted in a peptide synthesiser with washing processes and Fmoc-removal processes analogously to Example 15.
Couplin~ Val, Gln, Gly, Leu and Arg are coupled in the form of Fmoc-amino acid 2,4,5-trichlorophenyl ester (0.72 mmol) in 1.20 ml of DMA
together with 1.44 ml of 0.5M HOBt/0.5M diisopropylethylamine in DMA at room temperature for 1 hour. The other amino acid derivatives are coupled in the form of symmetrical anhydrides (1.08 mmol) (preparation analogous to Example 10) for 1 hour at room temperature. In the case of amino acids Nos. 3, 8, 10, 11, 18, 20 and 21, the process is repeated (recoupling~.
When the synthesis is complete, the resin is washed 5 times ~ith isopropyl alcohol, the terminal Fmoc group being retained, and dried under a high vacuum.

Example 18- Fmoc-Ala-Tyr(But)-Arg(Mtr)-Pro-Ser(But)-Glu(OBut)-Thr(But)-Leu-Cys(Trt)-Gly-Gly-Glu-(oBut-)-Leu-val-As~ oBut~-Th-r(But)-Leu-Gln-Phe-Val-Cys(SBut)-Gly-OH (side chain-proteoted IGF-2 (1_22?-docosapeptide) 1.80 g of (12) ~approximately 0.19 mmol) from Example 17 are mixed for 1.5 hours at room temperature with 35 ml of dichloromethane/acetic acid (9:1 vol.). The resin is filtered off and the difficultly soluble fragment is extracted at 60C as follows: 3 x 50 ml dimethyl sulphoxide (DMSO), 3 x trlfluoroethanolldichloromethane (1:1 vol.), 1 x N-methyl-pyrrolidone/DMSO (8:2 vol.). The combined flltrates are concentrated by evaporation under a high vacuum and the residue is stirrsd for 1 hour at 50C with 5 ml of water/methanol (5:95 vol.). The undissolved material is filtered off and dri~d at roorn temperature under a high vacuum. The extremely difflcultly soluble fragment cannot be analysed by the HPLC

technique. TLC (2 systems): the product i9 more than 90 % strength (dissolved in DMSO/N-methylpyrrolidone (2:8)). FAB MS_ mass peak 3539 (M~Na ).
xample 19: O-[FMoc-Ala-Ty_(But)-Arg(Mtr)-Pro-Ser(B-tt)-Glu(OBut)-Thr(But)-Leu-Cys(Trt)-Gly]-hy roxy resin (side chain-protected IGF-? (I-10)-undecapeptide bonded to h~_oxy resin), (13) ].00 g of O-[Fmoc-Gly]-hydroxy resin (6) (approximately 0.36 mmol) is reacted in a peptide synthesiser wlth washing processes and Fmoc-removal processes analogous1y to Example 15.
Coupling: the amino acid derivatives are coupled in the form of symmetrical anhydrides (1.08 mmol) (preparation analogous to Example 10) for 1 hour at room temperature. In the case of amino acids Nos. 3, 8 and 9 the coupling process is repeated with 2 equivalents of 2,4,5-trichloro-phenyl ester. When the synthesis is complete the resin i9 washed 5 times with isopropyl alcohol, the terminal Fmoc group being retained, and dried under a high vacuum.
xample 20: Fmoc-Ala-Tyr(But)-Arg(Mtr)-Pro-Ser(But)-Glu(OBut)-Thr(But)-Leu-Cys(Trt)-Glv (side chain-orotected IGF-2 (l-10)-un-.. . . . _ . _ . . _ . _ . ..
decapeptide)1.50 g of (13) (approximately 0.19 mmol) from Example 19 are mixed for 1. 5 hours at room temperature with 30 ml of dichlorome~hanelacetic acid (9:1 vol.). The resin is iiltered off and the filtrate is concentrated in vacuo and lyophiliced under a high vacuum. The resulting colourless pow~
der is for the purposes of purification partitioned ln an automatic coun-tercurrent partitioning sp2aratus (5 ml/phase) with the same mixture as in Example 13 over 1330 stages. Fractions 65-111 contain the pure title compound (TLC, HPLC) and are together concentrated by evaporation. The residue is triturated with ether and ~iltered. According to TLC (5 sy-stems on silica gel) and HPLC, the colourless powder is homogeneous.
Retention tlme 24.1 mins. on Nucleosil column 5C1a, 4.6 x 250 mm, gra-dient 50 % A/50 % B ~ O % AtlOO % B in 30 mins., A = 0.1 ~0 TFAJwater, B =
0.1 % TFA/acetonitrile, 1.0 ml/min., detection at 215 nm.

~ 3 ~ 2 Example_21: O-[Asn-Phe-Phe-D-Trp-Lvs(Boc)-rhr(But)-PIle--Gaba]-hydroxy . ~
resin (side chain-protected ~Tna~statin-D-T_ ~ -4- mino-butyric acid(l2)-(5-12)-octapeptide boncled to hydroxy resLn), (14) 1.00 g of O-[Fmoc-Gaba]-hyclroxy resin (produced analogously to Example 8 with 4 aminobutyric acid instead of glycine) (approximately 0.31 mmol) is reacted in a peptLde synthesiser with washing processes and Fmoc-removal processes analogously to Example 15.
Coupling: the amino acid derivatives are coupled in the form of symmet-rical anhydrides (0.93 mmol) (preparatlon analogous to Example 10) for 1 hour at room temperature. Phe and Asn are coupled in the form of 2,4,5-trichlorophenyl ester (2 equivalents). Recoupling is carried out with amino acid 1 (Asn). When the synthesis is complete, and after the terminal ~moc group has been removed, the resin is washed 5 times with isopropyl alcohol and dried under a high vacullm.
xample 22: H-Asn-Phe-Phe-D-Trp-Lys(Boc)-Thr(But)-Phe-Gaba-OH (side chain-protected somatostatin-D-Trp(8)-4-aminobutyric acid(12)-(5-12)-octapeptide) 1.38 g of (14) (approximately 0.26 mmol) from Example 21 are mixed for 1 hour at 50C with 5 ml of 5 % pyridine hydrochloride in DMA. The resin is filtered off and washed with DMSO, the filtrate is concentrated under a high vacuum and lyophilised once from DMSO and twice from tert.-butyl alcohol. According to HPLC the resulting colourless powder is more than 95 % pure and in HPLC and TLC is identical to an authentic specimen that has been produced by synthe~is in solution. IIPLC retention time 20.6 mins., Nucleosll column 5C18, 4.6 x 250 mm, gradient 100 % A¦O % B -~10 % A/90 ~0 B in 30 mins., A ~ 0.1 % TFA/water, B ~ 0.1 % TFA/~ceto-nitrile, 1.0 ml/min. 7 detection at 215 nm.

Claims (17)

1. A synthetic resin based on a polystyrene that can be used as a support for solid phase peptide synthesis and that has been cross-linked with from 0 to 5 mol% of divinyl benzene, characterised in that it has been substituted at benzene rings of its skeletal structure by groups of the formula (I) in which X represents -O- or -NH- and R represents C1-C4-alkyl.
2. A synthetic resin according to claim 1 in which the polystyrene is in the form of a copolymer with from 1 to 2 mol% divinyl benzene.
3. A synthetic resin according to claim 1 or 2 in which in formula I X
represents -O- and R represents methyl.
4. A synthetic resin according to claim 1 or 2 in which in formula I X
represents -NH- and R represents methyl.
5. A process for the manufacture of a synthetic resin based on a poly-styrene that can be used as a support for solid phase peptide synthesis, that has been cross-linked with from 0 to 5 mol% of divinyl benzene, and that has been substituted at benzene rings of its skeletal structure by groups of the formula (I) in which X represents -O- or -NH- and R represents C1-C4-alkyl, charac-terised in that a polystyrene that can be used as a support for solid phase peptide synthesis, has been cross-linked with from 0 to 5 % of divinyl benzene and has been chloromethylated or bromomethylated at benzene rings of its skeletal structure, is reacted in succession a) with a compound of formula (II) in which M is an alkali metal and R has the meaning mentioned herein-before, b) with a reducing agent and, if X represents -NH-, c) with a reagent that introduces the amino group.
6. A process according to claim 5, characterised in that the reaction is carried out with a compound of formula II in which M represents casesium.
7. A process according to claim 5, characterised in that in step b) reduction is carried out with a complex hydride or diborane.
8. A process according to any one of claims 5 to 7, characterised in that the reaction is carried out with a compound of formula II in which R
represents methyl.
9. A process for the manufacture of peptides and peptide amides, charac-terised in that a synthetic resin defined in claim 1 is used as a support for the solid phase synthesis.
10. A process according to claim 9, characterised in that peptides or peptide amides protected at the N-terminal and/or at other functional groups are manufactured.
11. A process according to claim 9, characterised in that a) the synthetic resin is reacted with a compound of formula W1-AM1-Y-H
in which Y represents -O- or -NH-, W1 represents an N-terminal amino-protecting group and AM1 represents the acyl radical of an amino acid sequence consisting of from 1 to 25 amino acid residues which is, if desired, protected at functional groups, or with a reactive functional derivative thereof, for the purpose of attaching the W1-AM1- residue to an -X- group of the resin, wherein X represents -O- or -NH-, b) the N terminal protecting group W1 is removed, c) the freed N-terminal amino group is acylated by reaction with an acid of formula W2-AM2-OH in which W2 and AM2 have meanings analogous to those of the above-defined radicals W1 and AM1, or with a reactive functional derivative thereof, d) the operation of alternate removal according to b) and acylation according to c) is repeated as required until the desired amino acid sequence is obtained and e) the resulting peptide or peptide amide, if required after removal or with simultaneous removal of protecting groups, in detached from the resin by acidolysis.
12. A process according to claim 11, characterised in that an amino-pro-tecting group W1 or W2 that can be removed under basic conditions is used to protect the N-terminal amino group and the removal according to process step b) is carried out with a base.
13. A process according to claim 12, characterised in that the 9-fluore-nylmethoxycarbonyl group (Fmoc) is used as the amino-protecting group W1 or W2 that can be removed under basic conditions.
14. A process according to any one of claims 11 to 13, characterised in that in process step a) a synthetic resin in which X represents -O- is reacted with an acid of formula W1-AM1-OH in which W1 and AM1 have the meanings given in claim 11, or with a reactive functional derivative thereof, and the end product is removed in acidic form.
15. A process according to any one of claims 11 to 13, characterised in that in process step a) a synthetic resin in which X represents -O- is reacted with an amide of formula W1-AM1-NH2 in which W1 and AM1 have the meanings given in claim 11, and the end product is removed in the form of a peptide amide.
16. A process according to any one of claims 11 to 13, characterisd in that in process step a) a synthetic resin in which X represents -NH- is reacted with an acid of formula W1-AM1-OH in which W1 and AM1 have the meanings given in claim 11, or with a reactive functional derivative thereof, and the end product is removed in the form of a peptide amide.
17. A synthetic resin based on a polystyrene that can be used as a support for solid phase peptide synthesis and that has been cross-linked with from 0 to 5 mol% of divinyl benzene, characterised in that it has been substituted at benzene rings of its skeletal structure by groups of the formula (I) in which the -X-H group is replaced by a -NH-W, -X-AM-W or -X-AM-H
group in which -X- represents -O- or -NH-, W represents an N-terminal amino-protecting group and AM represents the acyl radical of an amino acid sequence consisting of from 1 to 180 amino acid residues which 18, if required, protected at functional groups.
CA000562701A 1987-03-30 1988-03-28 Synthetic resin Expired - Lifetime CA1318462C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA000616052A CA1322008C (en) 1987-03-30 1991-05-01 Intermediate for synthetic resin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH121487 1987-03-30
CH1214/87-1 1987-03-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA000616052A Division CA1322008C (en) 1987-03-30 1991-05-01 Intermediate for synthetic resin

Publications (1)

Publication Number Publication Date
CA1318462C true CA1318462C (en) 1993-05-25

Family

ID=4205167

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000562701A Expired - Lifetime CA1318462C (en) 1987-03-30 1988-03-28 Synthetic resin

Country Status (19)

Country Link
US (3) US4859736A (en)
EP (1) EP0285562B1 (en)
JP (1) JP2513775B2 (en)
KR (1) KR950013679B1 (en)
AT (1) ATE88726T1 (en)
AU (1) AU615181B2 (en)
CA (1) CA1318462C (en)
DD (3) DD296087A5 (en)
DE (1) DE3880541D1 (en)
DK (1) DK175042B1 (en)
ES (1) ES2054863T3 (en)
FI (1) FI90780C (en)
GR (1) GR3007996T3 (en)
HU (1) HU208155B (en)
IE (1) IE61485B1 (en)
IL (1) IL85884A (en)
MX (1) MX10917A (en)
PT (1) PT87105B (en)
YU (1) YU62588A (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
HU206890B (en) * 1986-10-13 1993-01-28 Sandoz Ag Process for producing sugar-modified somatostatin peptide derivatives and pharmaceutical compositions containing them as active components
US4859736A (en) * 1987-03-30 1989-08-22 Ciba-Geigy Corporation Synthetic polystyrene resin and its use in solid phase peptide synthesis
US5242974A (en) * 1991-11-22 1993-09-07 Affymax Technologies N.V. Polymer reversal on solid surfaces
US5212288A (en) * 1990-02-20 1993-05-18 Syntex (U.S.A.) Inc. Temporary minimal protection synthesis of serine-containing polypeptides
US5155166A (en) * 1990-06-18 1992-10-13 Eastman Kodak Company Use of 1-(1-pyrrolidinylcarbonyl)pyridinium salts to attach compounds to carboxylated particles and a kit containing same
US5071565A (en) * 1991-02-04 1991-12-10 Iowa State University Research Foundation, Inc. Modified resins for solid-phase extraction
US5550215A (en) * 1991-11-22 1996-08-27 Holmes; Christopher P. Polymer reversal on solid surfaces
US5268423A (en) * 1992-02-28 1993-12-07 New York University Method for preparation of peptide synthesis resins and peptide synthesis resins
IE921942A1 (en) * 1992-06-16 1993-12-29 Gary A Siwruk John S Eynon Liquid phase synthesis of peptides and peptide derivatives
US5516891A (en) * 1992-06-16 1996-05-14 Kinerton, Ltd. Liquid phase synthesis of peptides and peptide derivatives
US5463564A (en) * 1994-09-16 1995-10-31 3-Dimensional Pharmaceuticals, Inc. System and method of automatically generating chemical compounds with desired properties
WO1998020459A1 (en) 1996-11-04 1998-05-14 3-Dimensional Pharmaceuticals, Inc. System, method, and computer program product for the visualization and interactive processing and analysis of chemical data
US6571227B1 (en) 1996-11-04 2003-05-27 3-Dimensional Pharmaceuticals, Inc. Method, system and computer program product for non-linear mapping of multi-dimensional data
US6453246B1 (en) 1996-11-04 2002-09-17 3-Dimensional Pharmaceuticals, Inc. System, method, and computer program product for representing proximity data in a multi-dimensional space
US6392010B1 (en) 1996-12-19 2002-05-21 Aventis Pharmaceuticals Inc. Process for the solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and αβ-unsaturated carboxylic acid and aldehyde compounds
GB9717173D0 (en) 1997-08-13 1997-10-22 Akzo Nobel Nv Solid phase supports
US6114468A (en) * 1998-06-01 2000-09-05 Novartis Ag Synthetic resins for use in solid phase synthesis
US7416524B1 (en) 2000-02-18 2008-08-26 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. System, method and computer program product for fast and efficient searching of large chemical libraries
US6671627B2 (en) 2000-02-29 2003-12-30 3-D Pharmaceuticals, Inc. Method and computer program product for designing combinatorial arrays
US7039621B2 (en) 2000-03-22 2006-05-02 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. System, method, and computer program product for representing object relationships in a multidimensional space
AU2001249805A1 (en) 2000-04-03 2001-10-15 3-Dimensional Pharmaceuticals, Inc. Method, system, and computer program product for representing object relationships in a multidimensional space
CA2419600A1 (en) * 2000-08-22 2002-02-28 3-Dimensional Pharmaceuticals, Inc. Method, system, and computer program product for determining properties of combinatorial library products from features of library building blocks
WO2002025504A2 (en) * 2000-09-20 2002-03-28 Lobanov Victor S Method, system, and computer program product for encoding and building products of a virtual combinatorial library
WO2002061419A1 (en) * 2001-01-29 2002-08-08 3-Dimensional Pharmaceuticals, Inc. Method, system, and computer program product for analyzing combinatorial libraries
WO2002083606A1 (en) * 2001-04-17 2002-10-24 University Of Alberta A linker system for the synthesis and screening of combinatorial libraries of polyamine derivatives on water compatible supports
DE60304184T2 (en) * 2002-01-25 2006-12-28 Phenomenex, Inc., Torrance SURFACE-PROOF-MODIFIED RESINS AND THEIR PREPARATION
US6926823B2 (en) * 2002-06-03 2005-08-09 Varian, Inc. Polymer with superior polar retention for sample pretreatment
US20070055048A1 (en) * 2003-07-04 2007-03-08 Vincent Cool Process for supported phase synthesis
EP1630600A3 (en) * 2004-07-29 2006-03-22 Rohm and Haas Electronic Materials, L.L.C. Hot melt composition and method involving forming a masking pattern
WO2006060803A2 (en) * 2004-12-03 2006-06-08 Polnox Corporation One pot process for making polymeric antioxidants
CA2761265C (en) * 2009-05-06 2017-12-19 Mallinckrodt Llc Solid support for fmoc-solid phase synthesis of peptide acids
HUE054006T2 (en) 2011-12-28 2021-08-30 Chugai Pharmaceutical Co Ltd Peptide-compound cyclization method
EP3071544B1 (en) 2013-11-22 2022-07-06 Polnox Corporation Macromolecular antioxidants based on dual type moiety per molecule: structures methods of making and using the same
US20180251695A1 (en) 2017-03-01 2018-09-06 Polnox Corporation Macromolecular Corrosion (McIn) Inhibitors: Structures, Methods Of Making And Using The Same
CN110799520A (en) 2017-06-09 2020-02-14 中外制药株式会社 Method for synthesizing peptides containing N-substituted amino acids
WO2019117274A1 (en) * 2017-12-15 2019-06-20 中外製薬株式会社 Method for producing peptide, and method for processing bases
JPWO2020111238A1 (en) 2018-11-30 2021-10-21 中外製薬株式会社 Deprotection method for peptide compounds or amide compounds, resin removal method for solid-phase reaction, and method for producing peptide compounds.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE141977C (en) *
GB1406611A (en) * 1971-08-17 1975-09-17 Leo Ab Pharmaceutically active secondary phosphoric acid esters
DD141977A3 (en) * 1975-07-11 1980-06-04 Jens Fischer PROCESS FOR PREPARING WATER-SOLUBLE ENZYME POLYSTYRENE COMPLEXES
US4301045A (en) * 1977-05-02 1981-11-17 Armour Pharmaceutical Company Synthesis of peptides
US4507230A (en) * 1982-05-12 1985-03-26 Research Corporation Peptide synthesis reagents and method of use
US4569967A (en) * 1983-10-24 1986-02-11 The Salk Institute For Biological Studies Synthesis of N-substituted peptide amides
US4623484A (en) * 1984-05-24 1986-11-18 Research Corporation Process for peptide synthesis
GB2169901A (en) * 1984-12-11 1986-07-23 Lkb Biochrom Ltd method for a solid phase synthesis of a linear combination of amino acid residues.
US4731412A (en) * 1984-12-28 1988-03-15 The Salk Institute Biotechnology/Industrial Associates, Inc. Process and composition for amino-terminal, α-aspartyl and α-glutamyl dipeptide esters
US4716147A (en) * 1986-03-27 1987-12-29 Monsanto Company Synthetic airial peptides
CA1329124C (en) * 1987-02-02 1994-05-03 Jerald C. Sadoff Conjugate malaria vaccine
US4859736A (en) * 1987-03-30 1989-08-22 Ciba-Geigy Corporation Synthetic polystyrene resin and its use in solid phase peptide synthesis

Also Published As

Publication number Publication date
DD296087A5 (en) 1991-11-21
PT87105B (en) 1992-07-31
DE3880541D1 (en) 1993-06-03
DK173088A (en) 1988-10-01
EP0285562A2 (en) 1988-10-05
US5004781A (en) 1991-04-02
AU615181B2 (en) 1991-09-26
JPS63260946A (en) 1988-10-27
HUT46713A (en) 1988-11-28
US4859736A (en) 1989-08-22
DK175042B1 (en) 2004-05-10
DK173088D0 (en) 1988-03-29
EP0285562A3 (en) 1990-01-10
KR950013679B1 (en) 1995-11-13
MX10917A (en) 1993-12-01
FI881451A0 (en) 1988-03-28
HU208155B (en) 1993-08-30
DD274033A5 (en) 1989-12-06
FI881451A (en) 1988-10-01
JP2513775B2 (en) 1996-07-03
ATE88726T1 (en) 1993-05-15
AU1381488A (en) 1988-09-29
PT87105A (en) 1988-04-01
GR3007996T3 (en) 1993-08-31
EP0285562B1 (en) 1993-04-28
FI90780B (en) 1993-12-15
DD284031A5 (en) 1990-10-31
FI90780C (en) 1994-03-25
IE880940L (en) 1988-09-30
IE61485B1 (en) 1994-11-02
KR880011210A (en) 1988-10-27
US5093530A (en) 1992-03-03
YU62588A (en) 1990-10-31
ES2054863T3 (en) 1994-08-16
IL85884A (en) 1992-01-15

Similar Documents

Publication Publication Date Title
CA1318462C (en) Synthetic resin
US4569967A (en) Synthesis of N-substituted peptide amides
Tam et al. Design and synthesis of multidetachable resin supports for solid-phase peptide synthesis
EP1179537B1 (en) Solid phase peptide synthesis method
US4855407A (en) Solid phase process for synthesizing peptides
US5175254A (en) Solid phase peptide synthesis using a polyacrylic support in aqueous solution
AU705716B2 (en) Nalpha-2-(4-nitrophenulsulfonyl)ethoxycarbonyl-amino acids
US4290943A (en) Method of preparing polypeptides
US4701499A (en) Synthesis of N-substituted peptide amides
EP0161468A2 (en) Process for the solid phase synthesis of peptides which contain sulfated tyrosine
US4301066A (en) Preparation of (D-Trp 6)-LH-RH via the heptapeptide H-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2
US4301045A (en) Synthesis of peptides
CN100357313C (en) Peptides having protected amines of untargeted sites, methods for production thereof and of specifically conjugated PEG peptides using the same
KR20030081355A (en) Process for the synthesis of a peptide having a Trp residue
US6075141A (en) N.sup.α -α, α-dimethyl-3,5-dialkoxybenzylcarbonyl amino acid 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazin-3-yl and pentafluorophenyl esters
CN114945580B (en) Method for synthesizing south Ji Botai
CA1333441C (en) Solid phase peptide synthesis
CA1271300A (en) Solid phase process for synthesizing peptides
NO177100B (en) peptides

Legal Events

Date Code Title Description
MKEX Expiry

Effective date: 20100525